Navigation Links
Arbor Pharmaceuticals Completes $34.8 Million Financing
Date:11/11/2010

owing pediatric market. The company intends to become a leading specialty pharmaceutical company by actively licensing, developing and commercializing late-stage products for specialty focused conditions. Arbor currently markets three products for varying otic conditions including XYLAREX®, ZINOTIC® and NEOTIC®, and also markets PEDIADERM™ HC COMPLETE KIT for atopic dermatitis, FLUORADAY® for fluoride supplementation, and RHINARIS® and SALTAIRE® for nasal hygiene.

For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

About JW Asset Management, LLC

JW Asset Management is a New York based fund manager for three investment partnerships. Jason Wild, a registered pharmacist, is the firm's founder and chief investment officer. JW Asset Management was founded in 1997 and has a strong history of finding opportunities within the specialty pharmaceutical sector. The firm is active in both the public and private equity markets.

About Signet Healthcare Partners

Signet Healthcare Partners was founded in 1998 and has a team that brings over 100 years of collective experience in the biopharmaceutical, medical device, private equity and investment banking businesses. Signet Healthcare has maintained its dedicated focus to diversified healthcare investing – primarily serving as lead investor to expansion stage companies engaged in specialty pharmaceuticals, medical devices and biopharmaceutical services.

About ARCH Healthcare Fund

ARCH Healthcare
'/>"/>

SOURCE Arbor Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DATATRAK Secures Safe Harbor Certification for EU and Switzerland
2. Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area
3. Arbor Pharmaceuticals Announces the Launch of Pediaderm(TM) HC Complete Kit - A Comprehensive Approach to the Management of Atopic Dermatitis
4. Harbor BioSciences to Receive Patent for Apoptone(R) Cancer Treatment
5. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
6. Cold Spring Publishing, LLC, Changes Name to Harborside Press, LLC
7. Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services
8. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
9. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for First Quarter Fiscal 2011
10. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
11. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 Inovio Pharmaceuticals, Inc. (NYSE MKT: ... call to report its second quarter 2014 financial results ... CEO Dr. J. Joseph Kim and CFO ... provide a corporate update, and participate in a live ... plans for VGX-3100, Inovio,s immune therapy targeting pre-cancers and ...
(Date:7/31/2014)... Indien, August 1, 2014 ... Inc. gaben heute bekannt, vor kurzem für ... zur Schmerzbehandlung nach chirurgischen Eingriffen eine kommerzielle ... der Europäischen Union und weiterer europäischer Länder ... und mit Ropivacain gefüllte OneDose ReadyfusOR später ...
(Date:7/31/2014)... 2014 IRIDEX Corporation (Nasdaq: IRIX ) ... months ended June 28, 2014.  , Revenues were ... from $9.2 million in the 2013 second quarter and up ... Revenues for the first six months of 2014 were $20.9 ... months of last year. , Gross margin for the ...
Breaking Medicine Technology:Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7
... Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) ... ) and Cephalon, Inc. (NASADQ: CEPH) on their announcement that ... to the news, Valeant has withdrawn its consent solicitation. ... for Cephalon stockholders and we are pleased that Teva has ...
... Solutions, Inc. (OTCQB: VHSLD) announced that it will begin ... Financial Industry Regulatory Authority has approved a change in ... ticker change has gone into effect for the trading ... the "D" will be removed from the ticker symbol ...
Cached Medicine Technology:Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction 2Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change 2
(Date:8/1/2014)... The North America Endpoint Security Market ... in North America with analysis and forecast of revenue. ... billion in 2014 to $4.77 billion by 2019, at ... Browse through the TOC of the North America Endpoint ... in-depth analysis provided. It also provides a glimpse of ...
(Date:8/1/2014)... 01, 2014 Over the past ... from innovative technologies that have enabled cosmetic dentists ... tooth color. Moreover, the burgeoning elderly population has ... tooth ailments. Due to long-term use of medications, ... have demanded dental fillings, veneers and implants. As ...
(Date:8/1/2014)... NY) Scientists at Albert Einstein College of ... that aid in digestion help keep the intestinal lining ... Immunity , could yield new therapies for inflammatory bowel ... , The research involved the intestinal microbiome, which contains ... in promoting or preventing disease is a major emerging ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Oxford ... company develops biomarkers. Its products include CytoSure heamatological ... +SNP Array, CytoSure ISCA UPD array, CytoSure ISCA ... array. OGT offers services, such as targeted sequencing ... service, miRNA analysis, gene expression analysis, cytosure services ...
(Date:8/1/2014)... Kathleen Doheny HealthDay Reporter ... Birth control pills containing high doses of estrogen, along ... breast cancer in women under 50, new preliminary ... explained lead researcher Elisabeth Beaber, a staff scientist at ... of these formulations increase breast cancer risk while other ...
Breaking Medicine News(10 mins):Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:'Normal' bacteria vital for keeping intestinal lining intact 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... www.stressballsuk.com ... points to an economic upturn and possibly the beginning of the end of the credit ... (PRWEB) March 2, ... to an economic upturn and possibly the beginning of the end of the credit crunch., ...
... ... event focusing on insights into the exploding field of neuroscience, what this means for ... the most effective ways to motivate and generate transformation in organisations – all leading ... ...
... ... to fill the gap in poor physician adherence to low back pain management guidelines with the ... ... for the iPhone platform this week to help bridge an expensive health care gap. The ...
Cached Medicine News:Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 2Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 3Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 4Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 5Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 6Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 7Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 8Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 9Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 10Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 11Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 12Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 13Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 14Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 2Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 3Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 2Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 3Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 5Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 6Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 7Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 8Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 9Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 10Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 11Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 12Health News:Promotional Stress Ball Supplier -- StressBallsUK.com Starts 2010 Strongest Ever 2Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines 2
... Fat Harvest, Wash & Transfer System is ... make fat transfer procedures simpler for the ... the need for an office-based technique. LipiVage™ ... is no longer a need to centrifuge, ...
... Type B) Injectable Solution, the only Botulinum ... demonstrated in numerous published studies to be ... Delivered as a purified, ready-to-use solution, ... a simpler way to significantly reduce abnormal ...
... BOTOX® Cosmetic is a simple, nonsurgical, physician-administered ... severe frown lines between the brows in ... age. It is the only treatment of ... Drug Administration (FDA). BOTOX® Cosmetic is ...
Inquire...
Medicine Products: